UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.687

Sortiert nach

Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro

Cancer research (Chicago, Ill.), 2001, Vol.61 (1), p.131-137

2001

Volltextzugriff (PDF)

Phase I Trial and Pharmacokinetic Study of the Farnesyltransferase Inhibitor Tipifarnib in Children With Refractory Solid Tumors or Neurofibromatosis Type I and Plexiform Neurofibromas

Journal of clinical oncology, 2006-01, Vol.24 (3), p.507-516

2006

Volltextzugriff (PDF)

Current status of clinical trials of farnesyltransferase inhibitors

Current opinion in oncology, 2001-11, Vol.13 (6), p.470-476

2001

Volltextzugriff (PDF)

Farnesyl protein transferase inhibitor ZARNESTRA R115777 - history of a discovery

Current topics in medicinal chemistry, 2003-01, Vol.3 (10), p.1095

2003

Volltextzugriff (PDF)

Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway

Investigational new drugs, 1999-08, Vol.17 (3), p.241-258

End, D W

1999

Volltextzugriff (PDF)

Chemoprevention of Benzo(a)pyrene-induced Lung Tumors in Mice by the Farnesyltransferase Inhibitor R115777

Clinical cancer research, 2003-05, Vol.9 (5), p.1927-1930

2003

Volltextzugriff (PDF)

Effects of the farnesyl transferase inhibitor R115777 (Zarnestra) on mammary carcinogenesis: prevention, therapy, and role of HaRas mutations

Molecular cancer therapeutics, 2006-04, Vol.5 (4), p.1073-1078

2006

Volltextzugriff (PDF)

Impact on farnesyltransferase inhibition of 4-chlorophenyl moiety replacement in the Zarnestra ® series

European journal of medicinal chemistry, 2007-05, Vol.42 (5), p.702-714

2007

Volltextzugriff (PDF)

Novel β-(imidazol-4-yl)-β-amino acids: solid-phase synthesis and study of their inhibitory activity against geranylgeranyl protein transferase type I

Bioorganic & medicinal chemistry letters, 2005-03, Vol.15 (6), p.1713-1719

2005

Volltextzugriff (PDF)

Efficacy of the farnesyltransferase inhibitor R115777 in a rat mammary tumor model: role of Ha-ras mutations and use of microarray analysis in identifying potential targets

Carcinogenesis (New York), 2006-07, Vol.27 (7), p.1420-1431

2006

Volltextzugriff (PDF)

5-Imidazolyl-quinolinones, -quinazolinones and -benzo-azepinones as farnesyltransferase inhibitors

Bioorganic & medicinal chemistry letters, 2003-05, Vol.13 (9), p.1543-1547

2003

Volltextzugriff (PDF)

Interactions of Abiraterone, Eplerenone, and Prednisolone with Wild-Type and Mutant Androgen Receptor: A Rationale for Increasing Abiraterone Exposure or Combining with MDV3100—Letter

Cancer research (Chicago, Ill.), 2013-05, Vol.73 (9), p.2926-2926

2013

Volltextzugriff (PDF)

Substituted azoloquinolines and -quinazolines as new potent Farnesyl Protein Transferase inhibitors

Bioorganic & medicinal chemistry letters, 2003-12, Vol.13 (24), p.4365-4369

2003

Volltextzugriff (PDF)

4-Methyl-1,2,4-triazol-3-yl heterocycle as an alternative to the 1-methylimidazol-5-yl moiety in the farnesyltransferase inhibitor ZARNESTRA

Bioorganic & medicinal chemistry letters, 2003-12, Vol.13 (24), p.4361-4364

2003

Volltextzugriff (PDF)

Discovery and Clinical Evaluation of 1-{N-[2-(Amidinoaminooxy)ethyl]amino}carbonylmethyl-6-methyl-3-[2,2-difluoro-2-phenylethylamino]pyrazinone (RWJ-671818), a Thrombin Inhibitor with an Oxyguanidine P1 Motif

Journal of medicinal chemistry, 2010-02, Vol.53 (4), p.1843-1856

2010

Volltextzugriff (PDF)

Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100

Cancer research (Chicago, Ill.), 2013-05, Vol.73 (9), p.2926-2926

2013

Volltextzugriff (PDF)

Nonclinical Safety Assessment of a Synthetic Peptide Thrombopoietin Agonist: Effects on Platelets, Bone Homeostasis, and Immunogenicity and the Implications for Clinical Safety Monitoring of Adverse Bone Effects

International journal of toxicology, 2011-08, Vol.30 (4), p.385-404

2011

Volltextzugriff (PDF)

Corrections to Discovery and Clinical Evaluation of 1-{N-[2-(Amidinoaminooxy)ethyl]amino}carbonylmethyl-6-methyl-3-[2,2-difluoro-2-phenylethylamino]pyrazinone (RWJ-671818), a Thrombin Inhibitor with an Oxyguanidine P1 Motif

Journal of medicinal chemistry, 2010-04, Vol.53 (8), p.3422-3422

2010

Volltextzugriff (PDF)

The Action of Adenosine Analogs on PC12 Cells

Journal of neurochemistry, 1981-12, Vol.37 (6), p.1431-1439

1981

Volltextzugriff (PDF)

Impact on famesyltransferase inhibition of 4-chlorophenyl moiety replacement in the Zamestra® series

European journal of medicinal chemistry, 2007, Vol.42 (5), p.702-714

2007

Volltextzugriff (PDF)

Nerve Growth Factor-Induced Alteration in the Response of PC12 Pheochromocytoma Cells to Epidermal Growth Factor

The Journal of cell biology, 1981-01, Vol.88 (1), p.189-198

1981

Volltextzugriff (PDF)

A rapid assay for measuring the metabolism of [ 3H]-retinoic acid in cell cultures

Journal of pharmacological and toxicological methods, 1995-12, Vol.34 (4), p.219-223

1995

Volltextzugriff (PDF)

The Induction of Ornithine Decarboxylase by Nerve Growth Factor and Epidermal Growth Factor in PC 12 Cells

Journal of neurochemistry, 1981-08, Vol.37 (2), p.342-349

1981

Volltextzugriff (PDF)

IN VITRO ASSESSMENT OF THE CENTRAL PRESYNAPTIC ACTIONS OF A SELECTIVE PHARMACOLOGICAL AGENT (MORPHINE) AND A NONSPECIFIC NEUROTOXIN (CHLORDECONE)

END, DAVID WILLIAM

1979

Volltextzugriff (PDF)

1 – 25 von 1.687

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.129)
Mit Volltextzugriff
(1.517)

Publikationsform

7 weitere anzeigen...

Weniger anzeigen...

Sprache

8 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Biological And Medical Sciences
(159)
Science & Technology
(135)
Medical Sciences
(117)
Life Sciences & Biomedicine
(108)
Humans
(104)
Exact Sciences And Technology
(76)
Chemistry
(62)
Biochemistry
(55)
Fundamental And Applied Biological Sciences. Psychology
(55)
Animals
(44)
Female
(43)
Male
(43)
General Medicine
(39)
Catalysis
(34)
General Chemistry
(33)
Organic Chemistry
(31)
Physics
(29)
Middle Aged
(26)
Physical Sciences
(26)
Adult
(25)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(40)

Menü

Weitere Dienste

Einstellungen

Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial

Phase I Trial and Pharmacokinetic Study of the Farnesyltransferase Inhibitor Tipifarnib in Children With Refractory Solid Tumors or Neurofibromatosis Type I and Plexiform Neurofibromas

Current status of clinical trials of farnesyltransferase inhibitors

Farnesyl protein transferase inhibitor ZARNESTRA R115777 - history of a discovery

Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway

Chemoprevention of Benzo(a)pyrene-induced Lung Tumors in Mice by the Farnesyltransferase Inhibitor R115777

Effects of the farnesyl transferase inhibitor R115777 (Zarnestra) on mammary carcinogenesis: prevention, therapy, and role of HaRas mutations

Impact on farnesyltransferase inhibition of 4-chlorophenyl moiety replacement in the Zarnestra ® series

Novel β-(imidazol-4-yl)-β-amino acids: solid-phase synthesis and study of their inhibitory activity against geranylgeranyl protein transferase type I

Efficacy of the farnesyltransferase inhibitor R115777 in a rat mammary tumor model: role of Ha-ras mutations and use of microarray analysis in identifying potential targets

5-Imidazolyl-quinolinones, -quinazolinones and -benzo-azepinones as farnesyltransferase inhibitors

Interactions of Abiraterone, Eplerenone, and Prednisolone with Wild-Type and Mutant Androgen Receptor: A Rationale for Increasing Abiraterone Exposure or Combining with MDV3100—Letter

Substituted azoloquinolines and -quinazolines as new potent Farnesyl Protein Transferase inhibitors

4-Methyl-1,2,4-triazol-3-yl heterocycle as an alternative to the 1-methylimidazol-5-yl moiety in the farnesyltransferase inhibitor ZARNESTRA

Discovery and Clinical Evaluation of 1-{N-[2-(Amidinoaminooxy)ethyl]amino}carbonylmethyl-6-methyl-3-[2,2-difluoro-2-phenylethylamino]pyrazinone (RWJ-671818), a Thrombin Inhibitor with an Oxyguanidine P1 Motif

Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100

Nonclinical Safety Assessment of a Synthetic Peptide Thrombopoietin Agonist: Effects on Platelets, Bone Homeostasis, and Immunogenicity and the Implications for Clinical Safety Monitoring of Adverse Bone Effects

Corrections to Discovery and Clinical Evaluation of 1-{N-[2-(Amidinoaminooxy)ethyl]amino}carbonylmethyl-6-methyl-3-[2,2-difluoro-2-phenylethylamino]pyrazinone (RWJ-671818), a Thrombin Inhibitor with an Oxyguanidine P1 Motif

The Action of Adenosine Analogs on PC12 Cells

Impact on famesyltransferase inhibition of 4-chlorophenyl moiety replacement in the Zamestra® series

Nerve Growth Factor-Induced Alteration in the Response of PC12 Pheochromocytoma Cells to Epidermal Growth Factor

A rapid assay for measuring the metabolism of [ 3H]-retinoic acid in cell cultures

The Induction of Ornithine Decarboxylase by Nerve Growth Factor and Epidermal Growth Factor in PC 12 Cells

IN VITRO ASSESSMENT OF THE CENTRAL PRESYNAPTIC ACTIONS OF A SELECTIVE PHARMACOLOGICAL AGENT (MORPHINE) AND A NONSPECIFIC NEUROTOXIN (CHLORDECONE)

Suchergebnisse filtern